Necrosulfonamide

Catalog No.S8251 Batch:S825101

Print

Technical Data

Formula

C18H15N5O6S2
Molecular Weight 461.47 CAS No. 1360614-48-7
Solubility (25°C)* In vitro DMSO 92 mg/mL (199.36 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Necrosulfonamide is a very specific and potent necrosis inhibitor and blocks mixed lineage kinase domain-like protein (MLKL).
Targets
necrosis(MLKL) [1]
In vitro

Necrosulfonamide inhibits MLKL-mediated Necrosis by blocking its N-terminal CC domain function. It blocks necrosis downstream of RIP3 activation. Necrosulfonamide has no effect on apoptosis induced by TNF-α plus Smac mimetic in non-RIP3-expressing Panc-1 cells, even at 5 μM concentration. The reason for the species specificity of necrosulfonamide is that the cysteine at residue 86 in human MLKL that is covalently modified by necrosulfonamide is replaced by a tryptophan residue in mouse MLKL(mixed lineage kinase domain-like protein)[2].
In vivo

Necrosulfonamide (NSA) is a small molecule that specifically inhibits necroptosis by targeting MLKL, the terminal executioner of necroptosis.

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    HT-29 cells

  • Concentrations

    1 μM

  • Incubation Time

    8 or 12 hrs

  • Method

    Necrosis inhibitors induce diverse effects on MLKL phosphorylation. HT-29 cells are treated with T/S/Z with or without necrosis inhibitors for 12 hr or 8 hr. The number of dead cells is determined by measuring released protease activity in culture medium. The whole-cell extracts are prepared and analyzed by western blotting. The final concentrations of 10 μM necrostatin-1 or 1 μM necrosulfonamide are used to block necrosis.
Animal Study:

[4]
  • Animal Models

    Male Wistar rats

  • Dosages

    1.65 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by , , Biochim Biophys Acta, 2018, 1865(3):522-531]

Data from [Data independently produced by , , Biochem Biophys Res Commun, 2018, 503(3):1550-1556]

Selleck's Necrosulfonamide has been cited by 89 publications

NR4A1 depletion inhibits colorectal cancer progression by promoting necroptosis via the RIG-I-like receptor pathway [ Cancer Lett, 2024, 585:216693] PubMed: 38301909
The cell fate regulator DACH1 modulates ferroptosis through affecting P53/SLC25A37 signaling in fibrotic disease [ Hepatol Commun, 2024, 8(3)e0396] PubMed: 38437058
Gasdermin D regulates soluble fms-like tyrosine kinase 1 release in macrophages [ Reprod Biol, 2024, 24(1):100857] PubMed: 38295720
Fatostatin induces ferroptosis through inhibition of the AKT/mTORC1/GPX4 signaling pathway in glioblastoma [ Cell Death Dis, 2023, 14(3):211] PubMed: 36966152
Hinokitiol-iron complex is a ferroptosis inducer to inhibit triple-negative breast tumor growth [ Cell Biosci, 2023, 13(1):87] PubMed: 37179385
NF-κB Inhibitor Myrislignan Induces Ferroptosis of Glioblastoma Cells via Regulating Epithelial-Mesenchymal Transformation in a Slug-Dependent Manner [ Oxid Med Cell Longev, 2023, 2023:7098313] PubMed: 36699318
Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR/GPX4 axis activated ferroptosis [ Front Pharmacol, 2023, 14:1110146] PubMed: 36744249
Flanking N- and C-terminal domains of PrsA in Streptococcus suis type 2 are crucial for inducing cell death independent of TLR2 recognition [ Virulence, 2023, 14(1):2249779] PubMed: 37641974
Flanking N- and C-terminal domains of PrsA in Streptococcus suis type 2 are crucial for inducing cell death independent of TLR2 recognition [ Virulence, 2023, 14(1):2249779] PubMed: 37641974
Anti-ferroptotic PRKAA2 serves as a potential diagnostic and prognostic marker for hepatoblastoma [ J Gastrointest Oncol, 2023, 14(4):1788-1805] PubMed: 37720445

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.